<DOC>
	<DOCNO>NCT00151541</DOCNO>
	<brief_summary>The purpose study compare safety efficacy 5 % Dapsone Topical Gel , ( DTG ) twice daily combination daily vehicle control , adapalene gel 0.1 % benzoyl peroxide gel 4 % . The second objective study determine dapsone exposure co-administration DTG 5 % vehicle control , adapalene benzoyl peroxide gel .</brief_summary>
	<brief_title>A Phase 3 Study Compare Safety Efficacy 5 % Dapsone Topical Gel , ( DTG ) Twice Daily Combination With Once Daily Vehicle Control , Adapalene Gel 0.1 % Benzoyl Peroxide Gel 4 %</brief_title>
	<detailed_description>This 3 arm , 12-week , randomize , double-blind , multicenter study compare safety efficacy DTG 5 % twice daily plus vehicle control daily vs. DTG 5 % twice daily plus adapalene gel 0.1 % daily vs. DTG 5 % twice daily plus 4 % benzoyl peroxide gel daily subject acne vulgaris . Approximately 300 male female subject , 12 year age old , acne vulgaris &gt; 20 inflammatory lesion ( papule and/or pustule ) &gt; 20 non-inflammatory lesion ( comedo ) mandibular line Baseline enrol . Follow-up visit occur Week 2 , 4 , 8 12 . Global Acne Assessments , Lesion Counts Local Adverse Reaction Assessments conduct visit . A physical exam do Baseline Week 12 . Plasma Dapsone Level sample draw Baseline , Week 2 Week 12/ET dapsone plasma level assessment . Adverse event concomitant medication assess throughout study .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Study subject consider participation base upon medical history finding prestudy interview examination . They enrol accord follow condition : 1 . Each subject parent/guardian read sign inform assent and/or consent form require IRB regulation . If subject require someone read and/or interpret inform consent , statement fact document . If subject unable read legally acceptable representative unable read , impartial witness present entire inform consent discussion ensure accurate representation inform consent document give verbally . If subject understand English , validate translate informed consent agreement provide . If subject minor , signature parent guardian require per Institutional Review Board regulation . 2 . Male female subject , 12 year age old . 3 . A female subject childbearing potential must pregnant nursing . All female subject must practice effective method birth control determine Investigator . Any female sexually active must agree begin use effective method birth control , exclude hormonal birth control , become sexually active study . A female subject use hormonal birth control must stable dose 3 month prior Baseline . Note : A surgically sterilized partner acceptable method birth control . 4 . A urine pregnancy test require female subject , 60 year age young prior treatment . If subject provide documentation surgical sterilization , baseline visit , pregnancy test require . Negative test result must obtain prior randomization . 5 . Subjects must good physical mental health . 6 . The subject must willing avoid swim bath 2 hour follow test article application . Additionally , subject must willing avoid moisturizers , sunscreens cosmetic 1 hour follow test article application . 7 . The subject must score &gt; 2 Global Acne Assessment Score Baseline ( Appendix D ) . 8 . Subjects must clear diagnosis acne vulgaris face , minimum 20 inflammatory lesion ( pustule papule ) 20 noninflammatory lesion ( comedo ) mandibular line Baseline . If , judgment Investigator , subject 's acne treat systemic acne medication , enrol study . 9 . Subjects must willing undergo blood draw throughout study . 10 . The subject must willing able comply requirement protocol MEDICATIONS EXCLUDED IN THE ADMISSION CRITERIA WILL NOT BE PERMITTED DURING THE STUDY . Subjects meet follow criterion exclude study entry : 1 . Subjects use systemic immunosuppressive medication within 28 day prior Baseline throughout study . Intranasal and/or inhale corticosteriods acceptable throughout study stable standard dose , label within Package Insert . 2 . Subjects use topical agent acne ( include limit benzoyl peroxide , antibiotic , topical vitamin A derivates retinol retinoids , medicate cosmetic , cleanser ) within 14 day prior Baseline throughout study . This include counter medication cleanser contain acne treatment ingredient , e.g . benzoyl peroxide , salicylic acid . 3 . Subjects receive light therapy ( ultraviolet B , tan bed , laser , photodynamic treatment ) , systemic medication , skin treatment know affect acne inflammatory response within 28 day prior Baseline throughout study . This include limited : antibiotic , large dos ( &gt; 50,000 U/day ) vitamin A , hormone ( exclude use birth control ) , spironolactone , aldactone , aldactizide , cyproterone acetate , NSAIDS chemical exfoliative treatment ( alphahydroxy acid `` fruitwash , '' `` lunchtime '' phenol peel ) physical peel ( laser , `` dry ice '' peel ) . Shortterm treatment antibiotic NSAIDS study nonacne related condition acceptable provide exposure limit 14 day per course antibiotic 7 day per month NSAIDS . 4 . Subjects receive isotretinoin ( Accutane ) within three month prior Baseline throughout study . 5 . Subjects participate previous QLT USA , Inc. ( formerly Atrix Laboratories , Inc. ) dapsone topical gel study . 6 . Subjects medical condition , Investigator 's judgment , make subject inappropriate study candidate . 7 . Subjects condition would hinder accurate facial acne evaluation include excessive facial hair ( beard ) , excessive scarring , sunburn disfigurement . 8 . Subjects severe cystic acne acne conglobata . 9 . Subjects active develop nodule mandibular line Baseline . 10 . Subjects know allergy hypersensitivity dapsone , adapalene , benzoyl peroxide , component study product . 11 . Subjects take another investigational test article within 30 day prior Baseline throughout study . 12 . Female subject start new , change current hormonal contraceptive hormone replacement therapy within three month prior Baseline . Subjects receive Depo ProveraÂ® injection precede 4 month exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Acne Vulgaris</keyword>
	<keyword>Acne</keyword>
	<keyword>Dermatology</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Dapsone Topical Gel</keyword>
</DOC>